Search results for "Genetic testing"

showing 10 items of 193 documents

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

Havep53gene mutations and protein expression a different biological significance in colorectal cancer?*

2002

p53 alterations are considered the most common genetic events in many types of neoplasms, including colorectal carcinoma (CRC). These alterations include mutations of the gene and/or overexpression of the protein. The aim of our study was to assess whether in 160 patients undergoing resective surgery for primary operable CRC there was an association between p53 mutations and protein overexpression and between these and other biological variables, such as cell DNA content (DNA-ploidy) and S-phase fraction (SPF), and the traditional clinicopathological variables. p53 mutations, identified by PCR-SSCP-sequencing analysis, were found in 68/160 patients (43%) and positive staining for p53 protei…

Mutationmedicine.diagnostic_testPhysiologyColorectal cancerClinical BiochemistryCell BiologyGene mutationBiologymedicine.diseasemedicine.disease_causeMolecular biologyIntestinal mucosaDNA Mutational AnalysismedicineCancer researchImmunohistochemistryGeneGenetic testingJournal of Cellular Physiology
researchProduct

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder

2018

Psychiatric disorders are thought to have a complex genetic pathology consisting of interplay of common and rare variation. Traditionally, pedigrees are used to shed light on the latter only, while here we discuss the application of polygenic risk scores to also highlight patterns of common genetic risk. We analyze polygenic risk scores for psychiatric disorders in a large pedigree (n ~ 260) in which 30% of family members suffer from major depressive disorder or bipolar disorder. Studying patterns of assortative mating and anticipation, it appears increased polygenic risk is contributed by affected individuals who married into the family, resulting in an increasing genetic risk over generat…

Netherlands Twin Register (NTR)0301 basic medicineMajor Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics ConsortiumBipolar DisorderSAMPLEMedicine (miscellaneous)Pedigree chartDisease0302 clinical medicineSCHIZOPHRENIA2.1 Biological and endogenous factorsMedicineAetiologyANTICIPATIONlcsh:QH301-705.5Psychiatry0303 health sciencesDepressionASSOCIATIONSerious Mental IllnessPeer reviewMental HealthSchizophrenia/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMajor depressive disorderGeneral Agricultural and Biological SciencesEngineering sciences. Technologymedicine.medical_specialtyContext (language use)ArticlePsykiatriGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAGESDG 3 - Good Health and Well-beingddc:570Behavioral and Social Science/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_GeneticsPLINKGenetic TestingBipolar disorderPsychiatryBiology030304 developmental biologybusiness.industryPreventionHuman GenomeAssortative matingmedicine.diseaseBrain Disorders030104 developmental biologyMoodlcsh:Biology (General)Mood disordersAnticipation (genetics)ONSETHuman medicinebusiness030217 neurology & neurosurgery
researchProduct

germline mutations in women with familial breast cancer and a relative with haematological malignancy

2009

Biallelic inactivation of the ATM gene causes ataxia-telangiectasia (A-T), a complex neurological disease associated with a high risk of leukaemias and lymphomas. Mothers of A-T children, obligate ATM heterozygote mutation carriers, have a breast cancer (BC) relative risk of about 3. The frequency of ATM carriers in BC women with a BC family history has been estimated to be 2.70%. To further our clinical understanding of familial BC and examine whether haematological malignancies are predictive of ATM germline mutation, we estimated the frequency of heterozygote mutation carriers in a series of 122 BC women with a family history of both BC and haematological malignancy and without BRCA1/2 m…

OncologyCancer ResearchLymphomaDNA Mutational AnalysisCell Cycle ProteinsAtaxia Telangiectasia Mutated Proteins0302 clinical medicineBreast cancerGene FrequencyRisk FactorsMissense mutationGenetics0303 health scienceseducation.field_of_studyLeukemiafamilial breast cancerAtaxia–telangiectasiaPedigreeDNA-Binding ProteinsOncology030220 oncology & carcinogenesisMutation (genetic algorithm)EMMAFemaleAdultHeterozygotemedicine.medical_specialtyMolecular Sequence DataPopulationBreast NeoplasmsProtein Serine-Threonine KinasesBiologyRisk Assessment03 medical and health sciencesGermline mutationBreast cancerPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseGenetic TestingeducationAllele frequencyGerm-Line Mutation030304 developmental biologyBase SequenceTumor Suppressor ProteinsHeterozygote advantagemedicine.diseaseAtaxia-telangiectasia
researchProduct

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel …

2021

Background Hereditary breast cancer (BC), ovarian cancer (OC), and pancreatic cancer (PC) are the major BRCA-associated tumours. However, some BRCA1/2-wild-type (wt) patients with a strong personal and/or family history of cancer need a further genetic testing through a multi-gene panel containing other high- and moderate-risk susceptibility genes. Patients and methods Our study was aimed to assess if some BC, OC, or PC patients should be offered multi-gene panel testing, based on well-defined criteria concerning their personal and/or family history of cancer, such as earliness of cancer onset, occurrence of multiple tumours, or presence of at least two or more affected first-degree relativ…

OncologyCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia MedicaPALB2pancreatic cancerBreast NeoplasmsBreast cancerbreast cancerMUTYHInternal medicinePancreatic cancerMedicineHumansGenetic Predisposition to DiseaseGenetic TestingFamily historyCHEK2Original ResearchGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA1 ProteinCancermedicine.diseasePancreatic Neoplasmsovarian cancerOncologymulti-gene panel testingFemalegermline pathogenic variantsbusiness
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct

Familial colorectal cancer risk: ESMO Clinical Practice Guidelines.

2010

OncologyRiskmedicine.medical_specialtyHeterozygoteColorectal cancermedicine.medical_treatmentColonoscopyAntineoplastic AgentsPenetranceGastroenterologyDNA Mismatch RepairInternal medicinemedicinePrevalenceHumansGenetic TestingRisk factorSigmoidoscopyColectomyColectomyGenetic testingRandomized Controlled Trials as Topicmedicine.diagnostic_testProctocolectomybusiness.industryIncidenceProctocolectomy RestorativeCancerSigmoidoscopyHematologyColonoscopymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisCombined Modality TherapyEuropeOncologybusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Monoclonal antibodies in gastrointestinal cancers

2013

Introduction: Among gastrointestinal cancers, colorectal and gastric neoplasms are the most frequent. The development of new targeted drugs improved the efficacy of systemic therapy in advanced stages of those malignancies. Areas covered: This review highlights the main biological processes implicated in gastrointestinal cancer development and progression, such as angiogenesis and epidermal growth factor receptor (EGFR) signaling pathway. On these bases, anti-EGFR and anti-vascular endothelial growth factor (VEGF) monoclonal antibodies in colorectal and gastric cancer are discussed. Data about further monoclonal antibodies in development are also reported. Expert opinion: The use of monoclo…

OncologyVascular Endothelial Growth Factor AColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryPredictive Value of TestAntineoplastic AgentVascular Endothelial Growth Factor A; Animals; Antineoplastic Agents; Receptor Epidermal Growth Factor; Humans; Molecular Targeted Therapy; Predictive Value of Tests; Patient Selection; Antibodies Monoclonal; Genetic Testing; Individualized Medicine; Gastrointestinal Neoplasms; Tumor Markers Biological; Signal TransductionGastricDrug DiscoveryMonoclonalEpidermal growth factor receptorMolecular Targeted TherapyPrecision MedicineTumor MarkersColorectalCancerGastrointestinal NeoplasmsbiologyAntibody; Cancer; Colorectal; Gastric; Monoclonal; Animals; Antibodies Monoclonal; Antineoplastic Agents; Gastrointestinal Neoplasms; Genetic Testing; Humans; Individualized Medicine; Molecular Targeted Therapy; Patient Selection; Predictive Value of Tests; Receptor Epidermal Growth Factor; Signal Transduction; Tumor Markers Biological; Vascular Endothelial Growth Factor A; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalIndividualized MedicineErbB ReceptorsTumor Markers BiologicalGastrointestinal NeoplasmMonoclonalGastric NeoplasmHumanReceptorSignal Transductionmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsMonoclonal antibodyAntibodiesPredictive Value of TestsInternal medicinemedicineBiomarkers TumorAnimalsHumansGastrointestinal cancerGenetic TestingAntibodyPharmacologyEpidermal Growth Factorbusiness.industryAnimalDrug Discovery3003 Pharmaceutical SciencePatient SelectionCancermedicine.diseaseBiologicalbiology.proteinReceptor Epidermal Growth Factorbusiness
researchProduct

Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature

2018

Abstract Introduction. Prekallikrein (PK) and high-molecular-weight kininogen (HK) deficiencies are ultra-rare, autosomal-recessive defects of the contact system caused by biallelic mutations in the KLKB1 and KNG1 genes, respectively. Since affected subjects do not manifest a bleeding phenotype, a correct diagnosis is essential to prevent the administration of prohemostatic agents or plasma and to avoid delay of surgery. We describe a new case of PK deficiency identified at UMC Mainz. In addition, we performed a systematic review of the literature in order to i) collect blood material for genetic studies of reported PK deficient cases lacking this information, and ii) perform a comprehensiv…

Oncologymedicine.medical_specialtyMutationHematologymedicine.diagnostic_testbusiness.industryImmunologyPrekallikreinCell BiologyHematologymedicine.diseasemedicine.disease_causeCompound heterozygosityBioinformaticsBiochemistryHexokinase deficiencyInternal medicineMedicineDifferential diagnosisbusinessPyruvate kinase deficiencyGenetic testingScience meets clinical practice
researchProduct

In response: Genomic profile of breast cancer.

2015

Response to: Plun-Favreau J, Svedman C, Valentine W, Rouzier R. Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):393–94We would like to express our gratitude for th...

Oncologymedicine.medical_specialtyNational Health Programsmedia_common.quotation_subjectBreast NeoplasmsBreast cancerMammaPrintInternal medicineGratitudemedicineBiomarkers TumorHumansPharmacology (medical)Genetic TestingPrecision Medicinemedia_commonmedicine.diagnostic_testbusiness.industryHealth PolicyGene Expression ProfilingGeneral MedicineHealth Care Costsmedicine.diseaseGenomic ProfileFemaleOncotype DXbusinessExpert review of pharmacoeconomicsoutcomes research
researchProduct